Pirarubicin
Trials 15 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 22 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 213 trials | ||||||
| Phase 2 | NCT07378306 Background | Mar 2026 → Jun 2029 expected | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07410234 Background | Feb 2026 → Feb 2028 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06933394 Background | May 2025 → May 2031 expected | neuroblastoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06904183 Background | Apr 2025 → Mar 2029 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06714383 Background | Nov 2024 → Jul 2025 overdue | conventional osteosarcoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06397235 Background | May 2024 → Apr 2027 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05558722 Background | Dec 2022 → Aug 2024 overdue | female breast carcinoma | Xijing Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04954794 Background | Jul 2021 → Apr 2024 | hepatocellular carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04297280 Background | Apr 2020 → Jul 2023 | hepatocellular carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04126811 Comparator | Jun → Dec 2019 | soft tissue sarcoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03121833 Background | May 2017 → Dec 2019 | soft tissue sarcoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01430013 Background | Jun 2011 → Nov 2015 | T-cell non-Hodgkin lymphoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00131053 Background | Sep 2002 → May 2011 | acute lymphoblastic leukemia | Japan Adult Leukemia Study Group | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03342300 Comparator | Nov 2017 → Nov 2020 | poisoning | Peking University People's Hospital | Withdrawn | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07424287 Comparator | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06492395 Background | Aug 2024 → Jul 2026 overdue | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT02301091 Background | Oct 2014 → Oct 2018 | hepatocellular carcinoma | Ming Zhao | Unknown | No outcome recorded |
| Phase 3 | NCT02755311 Comparator | Mar 2014 → Jun 2016 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03892330 Comparator | Jun 2019 → Dec 2020 overdue | childhood kidney Wilms tumor | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02903524 Comparator | Sep 2016 → Sep 2018 | breast cancer | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01249690 Background | Jun 2010 → Jun 2012 | plasma cell myeloma | Second Military Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05287308 Background | Mar 2022 → Sep 2027 expected | breast cancer | Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pirarubicin | “CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin.” NCT06397235 ↗36“CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin.” NCT05582278 ↗ “TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision.” NCT04954794 ↗ “TACE is performed by using drug eluting beads, or using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision” NCT04297280 ↗ “For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization.” NCT06904183 ↗ “For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization.” NCT06492395 ↗ “Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone” NCT01430013 ↗ “A: epirubicin, pirarubicin or doxorubicin. Routine clinical dosage and administration shall be adopted.” NCT07410234 ↗ “Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1” NCT02584556 ↗ “CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization” NCT05263219 ↗ “A: Anthracyclines, including epirubicin, pirarubicin, and doxorubicin.” NCT07378306 ↗ “Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin.” NCT03277716 ↗ “Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22” NCT02396043 ↗ “Doxorubicin or pirarubicin， 50mg/m²， D1” NCT05527912 ↗ “Pirarubicin (THP) + Ifosfamide (IFO)” NCT03121833 ↗ “pirarubicin （50mg/m2, 1d Q3W)” NCT05558722 ↗ “pirarubicin(25mg/m2.d,d3-d5)” NCT06933394 ↗ |
| Known as | Adriamycin, tetrahydropyranyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2354444 ↗ |
| Known as | Pirarubicin hydrochloride | “Pirarubicin hydrochloride for injection.” NCT07424287 ↗ |
| Known as | Pirarubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2354444 ↗ |
| Known as | Pirarubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2354444 ↗ |
| Known as | Theprubicin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2354444 ↗ |
| Known as | THP | “single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.” NCT02923557 ↗3“A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed.” NCT03030157 ↗ “single immediate intravesical dose of pirarubicin (THP) intravesical therapy” NCT02740426 ↗ “Pirarubicin (THP) + Ifosfamide (IFO)” NCT03121833 ↗ |
| Known as | Thp-adm | ChEMBL registry synonym — accepted as the source's own label CHEMBL2354444 ↗ |
| Modality | Small molecule | — CHEMBL2354444 ↗ |
| Route | Other | “intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin” NCT02301091 ↗ |